Common Stock, par value $0.0001 per share
- Symbol
- ALLR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Allarity Therapeutics, Inc.
Other Events
Item 8.01 Other Matters. On September 28, 2026, Allarity Therapeutics, Inc. (the “Company”) announced the expansion of its in-house medical laboratory capabilities to include proteomics and cell line research. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Press release in this filing
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research →Company context
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer, and is using its proprietary DRP® technology to develop a companion diagnostic designed to identify patients expected to derive the greatest clinical benefit from stenoparib. Allarity’s principal operations are located in Denmark, and its U.S. business address is in Florida. For more information, visit www.allarity.com.
Current securities
Registered securities in this filing
ALLARITY THERAPEUTICS, INC. · 8-K · Filed 2026-09-29
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Matters.
On September 28, 2026, Allarity Therapeutics,
Inc. (the “Company”) announced the expansion of its in-house medical laboratory capabilities to include proteomics and cell
line research. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Filed exhibits (1)
Exhibit 99.1 Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research - Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity’s research capabilities to enable external partnerships TARPON SPRINGS, Fla., September 28, 2026 - Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121) - a differentiated, dual PARP and WNT pathway inhibitor - today announced that it has expanded the capabilities of its in-house medical laboratory to include proteomics and cell line research. The new capabilities build on the laboratory’s existing transcriptomics research and CLIA clinical testing services and are expected to support Allarity in several areas. Internally, the expanded capabilities will allow the Company to conduct additional research into the mechanism of action of its lead asset, stenoparib. Externally, these capabilities broaden the range of research projects and laboratory services that Allarity can offer to existing and prospect…
Open exhibit ↗